Clinical Trials Logo

Infection clinical trials

View clinical trials related to Infection.

Filter by:

NCT ID: NCT04521673 Recruiting - Clinical trials for Infectious Panuveitis

Pathogen Detection in Infectious Uveitis

Start date: October 1, 2020
Phase:
Study type: Observational

Infectious uveitis is a very important blinding disease. Some people who have been diagnosed with idiopathic uveitis may also have the activity of pathogens in the eye. However, due to the limitation of the amount of ocular samples, it is difficult to make a rapid and effective diagnosis of infection.Current study is to explore the infective cause of uveitis in China by using a broad diagnostic approach of detection.

NCT ID: NCT04520880 Not yet recruiting - Clinical trials for Hospitalized Patients

Antibodies Responses to COVID-19 Infection in Hospitalized Patients

No-SARS
Start date: August 2020
Phase:
Study type: Observational

1.5. Why this clinical study? The prevalence of seropositivity following SARS-CoV 2 infection might have its own potential benefits in terms of predicting the end of pandemic and the validity of herd immunity. It is not clear if SARS-CoV 2 infection would have a long-lasting antibody-mediated immunity, and if the antibodies' persistence is dependent on disease severity.depends on the severity of illness. If evidence is provided about the persistence of antibodies that is reflective of the protective immune response, serodiagnosis will be an important tool to identify individuals with various risk for infection, and those who are in need of receiving the forthcoming vaccines. The here proposed prospective clinical study will test the prevalence of seropositivity following SARS-CoV 2 infection in critically ill patients compared to those who do not require intensive care unit (ICU) admission or invasive ventilation with respect to the IgM and IgG levels.

NCT ID: NCT04519307 Active, not recruiting - Viral Infection Clinical Trials

Evaluation of Newborns Presenting With Suspected COVID 19

Start date: March 1, 2020
Phase:
Study type: Observational

This study evaluates the newborns who had respiratory symptoms at the neonatal intensive care admission

NCT ID: NCT04519034 Completed - Covid19 Clinical Trials

Vitamin D Status and Immune-inflammatory Status in Different UK Populations With COVID-19 Infection

Start date: September 1, 2020
Phase:
Study type: Observational

Hypothesis: Serum Vitamin D (25(OH)D) is significantly lower in severe versus non-severe COVID-19 infections and that this is a function of ethnicity. There is an association between vitamin D status and various cytokines (pro-inflammatory molecules). The primary objective of this research is to provide a snap shot of vitamin D status in patients from the South-East London area by age, sex, ethnicity and BMI and demonstrate ethnic differences in vitamin D status as well as its associations with severe vs non-severe COVID-19 infections. The secondary objective is to determine if there is an association between vitamin D status and various cytokines (pro-inflammatory molecules) and severity of disease.

NCT ID: NCT04516395 Not yet recruiting - Sepsis Clinical Trials

Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae

Start date: September 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the treatment outcomes in patients with CRE infections.

NCT ID: NCT04516187 Completed - Infection Clinical Trials

Recognition of Serious Infections in the Elderly

ROSIE
Start date: October 16, 2020
Phase:
Study type: Observational

The aim of this diagnostic accuracy study is to develop a clinical prediction rule based on signs, symptoms, patient characteristics and blood tests, to be used in ambulatory care to help physicians safely rule out a serious infection in an older patient. It will be performed in general practices and emergency care departments across Flanders (Belgium).

NCT ID: NCT04514016 Completed - Covid19 Clinical Trials

Cross Sectional CFAR HIV/COVID-19 Study

Start date: August 12, 2020
Phase:
Study type: Observational

The main purpose of this research study is to learn the rate of SARS COV-2 on HIV infected children, adolescents, and youth receiving their primary HIV care at the University of Miami Miller School of Medicine.

NCT ID: NCT04513821 Available - Clinical trials for Catheter-Related Infections

Expanded Access: Mino-Lok Therapy (MLT) for the Treatment of CRBSI/CLABSI

MLK
Start date: n/a
Phase:
Study type: Expanded Access

This is an Intermediate-Size Expanded Access, Open-Label Study for Use of Mino-Lok Therapy (MLT) in Combination with Systemic Antibiotics in the Treatment of Central Line Associated Bloodstream Infection. Mino-Lok may be made available for patients who otherwise do not qualify for the phase 3 clinical trial (NCT02901717 )

NCT ID: NCT04513158 Recruiting - Covid19 Clinical Trials

Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection

Start date: August 14, 2020
Phase: Phase 2
Study type: Interventional

This study proposes to evaluate the therapeutic efficacy, immunologic effects and normalization of laboratory parameters for patients at high risk for mortality when infected by SARS-CoV-2 (COVID-19) when administered one unit (approximately 200 mL) of convalescent plasma administered over a period of one hour. Following administration of the convalescent plasma, physical exam/clinical assessment information is collected daily and routine lab result data is collected every three days.

NCT ID: NCT04512118 Completed - Clinical trials for Presence of COVID-19 Compatible CT Abnormalities

CT Abnormalities Evocative of Lung Infection Are Associated With Lower 18F-FDG Uptake in Confirmed COVID-19 Patients

Start date: March 15, 2020
Phase:
Study type: Observational

CT signs that are evocative of lung COVID-19 infections have been extensively described, whereas 18F-FDG-PET signs have not. Our current study aimed to identify specific COVID-19 18F-FDG-PET signs in patients that were (i) suspected to have a lung infection based on 18F-FDG-PET/CT recorded during the COVID-19 outbreak and (ii) whose COVID-19 diagnosis was definitely established or excluded by appropriate viral testing.